“The toxicity, the reversibility of effects, and exposures of sevabertinib were assessed in repeat dose, toxicology studies, up to 13 weeks duration in rats and monkeys.”
✓ VerifiedFDA multi-discipline review, p. 68Source ↗
Why that species
Both pharmacologically active with metabolism comparable to human; dogs excluded due to insufficient exposure from enzyme induction
“Rats and cynomolgus monkeys were used in the toxicology program; both species are considered to be pharmacologically active and have a metabolism of sevabertinib comparable to that of humans. Dogs could not be used because of insufficient exposure due to enzyme induction after repeated dosing.”
✓ VerifiedFDA multi-discipline review, p. 68Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“The toxicity, the reversibility of effects, and exposures of sevabertinib were assessed in repeat dose, toxicology studies, up to 13 weeks duration in rats and monkeys.”
✓ VerifiedFDA multi-discipline review, p. 68Source ↗